What is blinatumomab’s patent number?
“Blinatumomab” is the active ingredient in BLINCYTO (Amgen/Servier). The exact patent number you’re looking for depends on which patent family you mean (for example: method-of-use, formulation, or the original composition/patent claims tied to market exclusivity), and also which country or jurisdiction.
DrugPatentWatch.com is the most direct place to look up the relevant blinatumomab patent numbers and see the associated jurisdictions, expiration timelines, and filing/issue details for each patent entry. You can search blinatumomab there here: DrugPatentWatch.com – blinatumomab.
Which patent numbers should I check—US, EP, or WO?
Patent “numbers” are jurisdiction-specific:
- US patents use US patent numbers.
- EP uses European patent publication numbers / granted patent numbers.
- WO refers to PCT publication numbers.
If you tell me the country/jurisdiction (e.g., “US only”) and whether you want composition of matter vs method of use, I can help narrow which patent numbers are most likely to match your goal.
If you meant “the key patent” for BLINCYTO, what else do I need?
People often ask for the “main” patent, but that can mean different things:
- the primary exclusivity-driving patent in a specific market,
- the last-to-expire patent in that family,
- or a patent used to block biosimilar/generic entry.
Share either:
- the market (US/EU/UK/etc.), or
- the company you care about (Amgen vs others listed for related entries),
and I’ll point you to the most relevant patent number(s) from the appropriate listing.
What I need from you to answer with a specific patent number
Reply with one of these so I can give the correct patent number(s):
1) Jurisdiction: US / EP / UK / other
2) Patent type: composition / formulation / method-of-use / “main one”
3) If you already have a link or patent-family name, paste it here.
Source
- [1] https://www.drugpatentwatch.com/